Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
Vergoeding selumetinib (Koselugo) voor kinderen met neurofibromatose type 1
mei 2024